HSV-Mediated Delivery of Erythropoietin Restores Dopaminergic Function in MPTP-Treated Mice

Molecular Therapy

Volumn 14, Issue 5, 2006, Pages 710-715

  Puskovic, Veljko ^a   Wolfe, Darren ^b   Wechuck, James ^b   Krisky, David ^b   Collins, Jeff ^a   Glorioso, Joseph C ^b   Fink, David J ^a   Mata, Marina ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; erythropoietin; gene therapy; herpes simplex virus; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; ERYTHROPOIETIN; NEURITE PROMOTING FACTOR; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HERPES SIMPLEX VIRUS; HISTOLOGY; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PERIKARYON; RODENT; SUBSTANTIA NIGRA; VIRAL GENE DELIVERY SYSTEM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; DOPAMINE; ERYTHROPOIETIN; FEMALE; GENETIC VECTORS; MICE; MICE, INBRED C57BL; SIMPLEXVIRUS;

RODENTIA; SIMPLEXVIRUS;

EID: 33749260912     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2006.07.004     Document Type: Article

References (22)

1. Konishi Y., Chui D.H., Hirose H., Kunishita T., and Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. 609 (1993) 29-35
2. Morishita E., Masuda S., Nagao M., Yasuda Y., and Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76 (1997) 105-116
3. Sakanaka M., et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. USA 95 (1998) 4635-4640
4. Brines M.L., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. USA 97 (2000) 10526-10531
5. Campana W.M., and Myers R.R. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J. 15 (2001) 1804-1806
6. Campana W.M., and Myers R.R. Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury. Eur. J. Neurosci. 18 (2003) 1497-1506
7. Bianchi R., et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc. Natl. Acad. Sci. USA 101 (2004) 823-828
8. Digicaylioglu M., et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc. Natl. Acad. Sci. USA 92 (1995) 3717-3720
9. Digicaylioglu M., and Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412 (2001) 641-647
10. Dirnagl U., Simon R.P., and Hallenbeck J.M. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 26 (2003) 248-254
11. Genc S., et al. Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci. Lett. 298 (2001) 139-141
12. Signore A.P., et al. thropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J. Neurochem. 96 (2006) 428-443
13. Yamada M., Oligino T., Mata M., Goss J.R., Glorioso J.C., and Fink D.J. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc. Natl. Acad. Sci. USA 96 (1999) 4078-4083
14. Natsume A., et al. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA induced degeneration. Exp. Neurol. 169 (2001) 231-238
15. Puskovic V., et al. Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol. Ther. 10 (2004) 67-75
16. Kirik D., Georgievska B., and Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 7 (2004) 105-110
17. Brines M., and Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 6 (2005) 484-494
18. Genc S., Akhisaroglu M., Kuralay F., and Genc K. Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci. Lett. 321 (2002) 73-76
19. Kordower J.H., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
20. Lang A.E., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59 (2006) 459-466
21. Kotzbauer P.T., and Holtzman D.M. Expectations and challenges in the therapeutic use of neurotrophic factors. Ann. Neurol. 59 (2006) 444-447
22. Chattopadhyay M., Wolfe D., Mata M., Huang S., Glorioso J.C., and Fink D.J. Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. Mol. Ther. 12 (2005) 307-313